DaebongLS Co Ltd

DaebongLS Co Ltd has a market price of 10700.0 KRW and a market cap of 117145408300.0 KRW, with a price-to-earnings ratio of 11.65 and a price-to-book ratio of 0.83. The company's liquidity is characterized as medium, with a current ratio of 5.44 and a debt-to-equity ratio of 0.52. However, the company has a negative net cash position after subtracting total debt. In terms of profitability, DaebongLS Co Ltd has a return on equity of 7.12% and a return on assets of 3.8%. The company's operating income is 7281312840.0 KRW, and its net income is 10058593930.0 KRW. The gross profit is 28494755150.0 KRW, indicating a gross margin of 27.92%. These metrics suggest that the company is generating returns, but they are below the industry median for Pharmaceuticals. DaebongLS Co Ltd operates through two segments: the Pharmaceutical Active Ingredient Business and the Cosmetic Material Business. The company sells its products in both domestic and overseas markets. The revenue concentration is not specified, but the company's operations are primarily in Korea. The company also provides testing services for materials used on the skin and engages in real estate leasing. The company's growth trajectory is not explicitly stated, but the free cash flow is negative at -24227117100.0 KRW, and the capital expenditure is -39628918390.0 KRW. The operating cash flow is 8906318720.0 KRW, which is lower than the capital expenditure. This suggests that the company is investing heavily in its operations, which could indicate growth opportunities or challenges in cash flow management. The risk assessment for DaebongLS Co Ltd indicates a medium liquidity risk and a low dilution risk. The key flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events for DaebongLS Co Ltd include the latest financial snapshot, which provides the most recent data on the company's financial performance. The company's operations and financials are disclosed in the latest available data, but there are no specific recent filings or transcripts mentioned.